News

Jerusalem, Israel, January 6, 2003 - Teva Pharmaceutical Industries Limited (NASDAQ: TEVA) and H. Lundbeck A/S (CSE: LUN.CO) announced today the results of two phase III clinical studies with an immediate release formulation of etilevodopa, a soluble prodrug of levodopa, in advanced Parkinson's Disease (PD) patients. Etilevodopa was found to be well tolerated and as effective as levodopa. On the primary endpoint, shortened the time to clinical effect, etilevodopa did not demonstrate statistically significant superiority over standard levodopa. The studies - RAPID, conducted in North America, a Read More »

Jerusalem, Israel, January 14, 2003 - Teva Pharmaceutical Industries Limited (NASDAQ: TEVA) confirms that, as previously announced, the results of the two phase III clinical trials with rasagiline in advanced Parkinson's Disease (PD) patients, which Teva is currently conducting together with H. Lundbeck A/S, are expected in the next few months. Upon successful completion of these trials, Teva intends to submit a New Drug Application for the product to the U.S. Food and Drug Administration.Teva clarifies that media reports from yesterday and today regarding rasagiline were related to the articl Read More »

Jerusalem, Israel, January 15, 2003 - Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) announced today that the U. S. Food and Drug Administration has granted tentative approval for the company's ANDA for Carboplatin Injection, 50 mg, 150 mg, and 450 mg.Carboplatin Injection is the generic equivalent of Bristol-Myers Squibb's Paraplatin ®. The product is indicated for the treatment of cancer.The brand product has annual sales of approximately $ 513 million.U.S. Patent No. 4,657,927, which protects the brand product from generic competition, is currently scheduled to expire on April 14, 2004. Read More »

Jerusalem, Israel, January 21, 2003 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the Honourable Mr. Justice Jacob of the U.K. High Court of Justice Chancery Division Patents Court has ruled in favor of Teva and two other companies that two Merck patents covering Fosamax ® are invalid. Alendronate Sodium Tablets are the generic equivalent of Merck's Fosamax ® Tablets. The product is indicated for the treatment and prevention of osteoporosis in postmenopausal women and the treatment of Paget's disease. Annual branded sales of Fosamax ® in the U.K. are approximately 4 Read More »

Jerusalem, Israel, January 24, 2003 - Teva Pharmaceutical Industries Ltd. (Nasdaq:TEVA) announced today that the U.S. Food and Drug Administration (FDA) has granted final approval for the company's Mirtazapine Tablets, 15 mg and 30 mg. Shipment will begin immediately. This approval follows a December 18, 2002 decision by the U. S. District Court for the District of New Jersey granting summary judgment in Teva's favor on the issue of non-infringement with regard to Organon's Remeron® Patent No. 5,977,099. Mirtazapine tablets are the first AB-rated generic version of Organon's Remeron®, and are Read More »

Jerusalem, Israel, January 27, 2003 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that Dan Suesskind, Chief Financial Officer will present at the U.S. Bancorp Piper Jaffray Health Care Conference, to be held at The Pierre hotel, in New York City at 1:30 PM ET on Wednesday, January 29, 2003.Teva Pharmaceutical Industries Ltd., headquartered in Israel, is among the top 35 pharmaceutical companies and among the largest generic pharmaceutical companies in the world. Over 80% of Teva's sales are in North America and Europe. The company develops, manufactures and markets gener Read More »

CONFERENCE CALL SCHEDULED FOR 10:00 AM ET Jerusalem, Israel, January 27, 2003 - Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) announced today that it will release its fourth quarter and full year 2002 financial results on Tuesday, February 18, 2003, early in the morning Israel time (evening of Monday, February 17, 2003 ET).Teva will host a conference call and live webcast on Tuesday, February 18, 2003, at 10:00 AM ET to discuss these results. Investors and other interested parties may access a live webcast through Teva's web site at www.tevapharm.com. Please login at least 10 minutes pri Read More »

*Q4 Net income increased 53% to $137 million, EPS of $0.50, up 51% *Q4 Net sales increased 36% to $770 million *Q4 Global in-market sales of Copaxone® totaled $156 million, up 53% Jerusalem, Israel, February 18, 2003 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) today reported net income of $137 million for the fourth quarter ended December 31, 2002 and $0.50 per fully diluted share (post-split), an increase over the fourth quarter of 2001 of 53% and 51%, respectively. Net sales for the quarter increased 36% to $770 million, with North America accounting for 67% of these sales and Euro Read More »

Jerusalem, Israel, February 21, 2003 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U.S. Food and Drug Administration has approved the company's ANDAs for Tamoxifen Citrate Tablets USP, 10 mg and 20 mg. Shipments will begin immediately.Tamoxifen Citrate Tablets are the AB-rated generic equivalent of AstraZeneca's Nolvadex® Tablets, an anti-estrogen drug for the treatment of breast cancer. Annual Tamoxifen sales in the USA are more than $500 million.Teva Pharmaceutical Industries Ltd., headquartered in Israel, is among the top 35 pharmaceutical companies and among Read More »

Jerusalem, Israel, March 26, 2003 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U. S. Food and Drug Administration has granted tentative approval of the company's ANDA for Metformin HCl Extended-Release Tablets, 500 mg. The brand product's annual sales are approximately $410 million.Metformin HCl Extended-Release Tablets are the AB-rated generic equivalent of Bristol-Myers Squibb's antihyperglycemic drug, Glucophage® XR Tablets, which is indicated as an adjunct to diet to lower blood glucose levels in patients with type 2 diabetes. Teva Pharmaceutical Industries Read More »